Evidence map›Paper›PMID 40853039›Full record

ArticleInternational journal of STD & AIDS2026

Real-world persistence of bictegravir versus dolutegravir single-tablet regimens: A retrospective cohort study in a large urban Canadian HIV clinic.

Mona Loutfy, Negin Masoudifar, Jennifer McCully, Angela Underhill, V Logan Kennedy, Dileesha Fernando, Dylana Mumm, Taban Saifi, Hugh Ngo, Soodi Navadeh and 1 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of STD & AIDS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mona LoutfyMaple Leaf Medical Clinic, Toronto, ON, Canada.ORCID 0000-0001-7887-8997
Negin MasoudifarDepartment of Medicine, University of Toronto, Toronto, ON, Canada.
Jennifer McCullyMaple Leaf Medical Clinic, Toronto, ON, Canada.
Angela UnderhillMaple Leaf Medical Clinic, Toronto, ON, Canada.
V Logan KennedyMaple Leaf Medical Clinic, Toronto, ON, Canada.ORCID 0000-0002-7478-8596
Dileesha FernandoInstitute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada.
Dylana MummGilead Sciences Canada, Mississauga, ON, Canada.
Taban SaifiGilead Sciences Canada, Mississauga, ON, Canada.
Hugh NgoGilead Sciences Canada, Mississauga, ON, Canada.
Soodi NavadehGilead Sciences, Foster City, CA, USA.
Graham SmithMaple Leaf Medical Clinic, Toronto, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BackgroundSingle-tablet regimens (STRs) with integrase inhibitors, bictegravir (BIC) or dolutegravir (DTG), are favored in HIV treatment for their efficacy and convenience. This study compares persistence-time from initiation to discontinuation-between BIC/emtricitabine (FTC)/tenofovir alafenamide (TAF) and DTG-containing STRs at a Toronto HIV clinic

Indexed as

Anti-HIV AgentsHeterocyclic Compounds, 3-RingHeterocyclic Compounds, 4 or More RingsHIV InfectionsHIV Integrase InhibitorsAdultAmidesCanadaDolutegravirEmtricitabineFemaleHumansMaleMiddle AgedOxazinesPiperazinesAmidesAnti-HIV AgentsbictegravirDolutegravirEmtricitabineHeterocyclic Compounds, 3-RingHeterocyclic Compounds, 4 or More RingsHIV Integrase InhibitorsOxazinesPiperazinesPyridonesTabletsTenofovirBictegravirdiscontinuationintegrase inhibitorspersistencesingle tablet regimens

Identifiers

PMID40853039
PMCPMC12783377

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.